Patents by Inventor Grethe Rasmussen
Grethe Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7655766Abstract: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.Type: GrantFiled: April 30, 2007Date of Patent: February 2, 2010Inventors: Carsten Germansen, Bobby Soni, Grethe Rasmussen
-
Publication number: 20090030183Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: September 8, 2008Publication date: January 29, 2009Inventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7431921Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: GrantFiled: June 27, 2003Date of Patent: October 7, 2008Assignee: Maxygen ApSInventors: Poul Baad Rasmussen, Grethe Rasmussen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20080167218Abstract: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.Type: ApplicationFiled: April 30, 2007Publication date: July 10, 2008Inventors: Carsten GERMANSEN, Bobby SONI, Grethe RASMUSSEN
-
Patent number: 7381805Abstract: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.Type: GrantFiled: May 26, 2006Date of Patent: June 3, 2008Assignee: Maxygen Holdings, Ltd.Inventors: Carsten Germansen, Bobby Soni, Grethe Rasmussen
-
Publication number: 20080090764Abstract: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.Type: ApplicationFiled: April 30, 2007Publication date: April 17, 2008Inventors: Carsten GERMANSEN, Bobby SONI, Grethe RASMUSSEN
-
Publication number: 20070014763Abstract: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.Type: ApplicationFiled: September 18, 2006Publication date: January 18, 2007Inventors: Carsten GERMANSEN, Bobby SONI, Grethe RASMUSSEN
-
Publication number: 20070014762Abstract: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.Type: ApplicationFiled: September 18, 2006Publication date: January 18, 2007Inventors: Carsten GERMANSEN, Bobby SONI, Grethe RASMUSSEN
-
Publication number: 20070009478Abstract: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.Type: ApplicationFiled: May 26, 2006Publication date: January 11, 2007Inventors: Carsten Germansen, Bobby Soni, Grethe Rasmussen
-
Patent number: 7144574Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: GrantFiled: February 26, 2002Date of Patent: December 5, 2006Assignee: Maxygen ApSInventors: Poul Baad Rasmussen, Grethe Rasmussen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7094586Abstract: The present invention relates to transglutaminases and transglutaminase preparations obtained from lower fungi belonging to the class Oomycetes and unprecedented high-level expression is achievable by growing these coenocytium forming organisms, especially the strains Pythium sp., Pythium irregulare, Pythium dissotocum, Pythium periilum (or P. periplocum), Pythium torulosum, Pythium ultimum, Pythium aphanidermatum, Phytophthora cactorum, Phytophthora palmivora, Phytophthora porri, Phytophthora infestans, Phytophthora megasperma, Phytophthora cinnamomi and Phytophthora cryptogea; and a recombinant transglutaminase has been cloned and expressed, the enzyme and enzyme preparations being useful for cross-linking proteins, e.g. in flour, baked products, meat products, fish products, cosmetics, cheese, milk products, gelled food products and leather finishing, or as a glutaminase, e.g. in bread and other baked glutein-containing food products.Type: GrantFiled: June 7, 2002Date of Patent: August 22, 2006Assignee: Novozymes A/SInventors: Lisbeth Bech, Grethe Rasmussen, Torben Halkier, Mariko Okada, Lene Nonboe Andersen, Markus Sakari Kauppinen, Thomas Sandal
-
Publication number: 20040013644Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: June 27, 2003Publication date: January 22, 2004Applicants: Maxygen ApS, Maxygen Holdings Ltd.Inventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 6667167Abstract: The present invention relates to a storage-stable liquid formulation comprising a laccase comprising (i) a laccase, (ii) at least one polyalcohol, which formulation has a pH which is more alkaline than the pH optimum of the laccase. It is also an object of the invention to provide a method for improving the storage-stability of liquid formulations comprising a laccase and the use of said liquid formulations for a personal care application or for bleaching or for textile applications such as dyeing of fabrics.Type: GrantFiled: June 28, 2000Date of Patent: December 23, 2003Assignee: Novozymes A/SInventors: Niels Henrik Sorensen, Grethe Rasmussen, Lotte Rugholm Henriksen
-
Publication number: 20030170206Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: February 26, 2002Publication date: September 11, 2003Applicant: Maxygen ApSInventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20030119167Abstract: The present invention relates to cellulase preparations consisting essentially of a homogeneous endoglucanase component which is immunoreactive with an antibody raised against a highly purified ˜43 kD endoglucanase derived from Humicola insolens, DSM 1800, or which is homogenous to said ˜43 kD endoglucanase, may be employed in the treatment cellulose-containing fabrics for harshness reduction or color clarification or to provide a localized variation in the color of such fabrics, or it may be employed in the treatment of paper pulp.Type: ApplicationFiled: May 3, 2002Publication date: June 26, 2003Applicant: Novozymes A/SInventors: Grethe Rasmussen, Jan Moller Mikkelsen, Martin Schulein, Shamkant Anant Patkar, Fred Hagen, Carsten Mailand Hjort, Sven Hastrup
-
Publication number: 20030059914Abstract: The present invention relates to transglutaminases and transglutaminase preparations obtained from lower fungi belonging to the class Oomycetes and unprecedented high-level expression is achievable by growing these coenocytium forming organisms, especially the strains Pythium sp., Pythium irregulare, Pythium dissotocum, Pythium periilum (or P. periplocum), Pythium torulosum, Pythium ultimum, Pythium aphanidermatum, Phytophthora cactorum, Phytophthora palmivora, Phytophthora porri, Phytophthora infestans, Phytophthora megaspenna, Phytophthora cinnamomi and Phytophthora cryptogea; and a recombinant transglutaminase has been cloned and expressed, the enzyme and enzyme preparations being useful for cross-linking proteins, e.g. in flour, baked products, meat products, fish products, cosmetics, cheese, milk products, gelled food products and leather finishing, or as a glutaminase, e.g. in bread and other baked glutein-containing food products.Type: ApplicationFiled: June 7, 2002Publication date: March 27, 2003Applicant: Novozymes A/SInventors: Lisbeth Bech, Grethe Rasmussen, Torben Halkier, Mariko Okada, Lene Nonboe Andersen, Markus Sakari Kauppinen, Thomas Sandal
-
Patent number: 6428993Abstract: The present invention relates to transglutaminases and transglutaminase preparations obtained from lower fungi belonging to the class Oomycetes. Unprecedented high-level expression is achievable by growing these coenocytium forming organisms, especially the strains Pythium sp., Pythium irregulare, Pythium dissotocum, Pythium periilum (or P. periplocum), Pythium torulosum, Pythium ultimum, Pythium aphanidermatum, Phytophthora cactorum, Phytophthora palmivora, Phytophthora porri, Phytophthora infestans, Phytoph-thora megasperma, Phytophthora cinnamomi and Phytophthora cryptogea. Arecombinant transglutaminase has been cloned and expressed, the enzyme and enzyme preparations being useful for cross-linking proteins, e.g. in flour, baked products, meat products, fish products, cosmetics, cheese, milk products, gelled food products and leather finishing, or as a glutaminase, e.g. in bread and other baked glutein-containing food products.Type: GrantFiled: June 24, 1997Date of Patent: August 6, 2002Assignee: Novozymes A/SInventors: Lisbeth Bech, Grethe Rasmussen, Torben Halkier, Mariko Okada, Lene Nonboe Andersen, Markus Sakari Kauppinen, Thomas Sandal
-
Publication number: 20010036910Abstract: A cellulase preparation consisting essentially of a homogeneous endoglucanase component which is immunoreactive with an antibody raised against a highly purified ˜43kD endoglucanase derived from Humicola insolens, DSM 1800, or which is homogenous to said 43kD endoglucanase, may be employed in the treatment cellulose-containing fabrics for harshness reduction or color clarification or to provide a localized variation in the color of such fabrics, or it may be employed in the treatment of paper pulp.Type: ApplicationFiled: December 13, 2000Publication date: November 1, 2001Inventors: Grethe Rasmussen, Jan Moller Mikkelsen, Martin Schulein, Shamkant Anant Patkar, Fred Hagen, Carsten Mailand Hjort, Sven Hastrup
-
Patent number: 6277611Abstract: The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.Type: GrantFiled: May 23, 2000Date of Patent: August 21, 2001Assignee: Novozymeo A/SInventors: Anders Hjelholt Pedersen, Allan Svendsen, Palle Schneider, Grethe Rasmussen, Joel Cherry
-
Patent number: 6190879Abstract: A method for identifying a transglutaminase-producing microorganism based on a selective assay is disclosed.Type: GrantFiled: April 20, 1999Date of Patent: February 20, 2001Assignee: Novo Nordisk A/SInventors: Lisbeth Bech, Iben Angelica Nørrevang, Torben Halkier, Grethe Rasmussen, Thomas Schäfer, Jens Tønne Andersen